Literature DB >> 7429492

The changing spectrum of disease, etiology, and diagnosis of mucormycosis.

A M Marchevsky, E J Bottone, S A Geller, D K Giger.   

Abstract

During the 20 year interval from 1958 to 1978 a change in the spectrum of disease, etiology, and diagnosis of mucormycosis was observed at The Mount Sinai Hospital. Although the rhinocerebral and pulmonary forms of mucormycosis were still the most frequent forms of disease, hospital acquired cutaneous and subcutaneous infections emerged. Since 1974, 14 of 15 cases of mucormycosis were diagnosed during life. Rizopus species, especially R. rhizopodoformis, have been the etiologic agents identified in 13 of 14 culturally proven cases. The presence or absence of antirhizopus fungistatic activity and antirhizopus antibody in the sera of six of the patients was correlated with the severity of clinical disease. Preliminary results showed a relationship between the extent of disease and the degree of serum fungistatic activity that was independent of antibody production.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7429492     DOI: 10.1016/s0046-8177(80)80054-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  30 in total

1.  Pulmonary mucormycosis presenting as massive fatal hemoptysis in a hemodialytic patient with chronic renal failure.

Authors:  S Yagihashi; K Watanabe; K Nagai; M Okudaira
Journal:  Klin Wochenschr       Date:  1991-03-18

2.  Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy.

Authors:  Shane M Devlin; Bing Hu; Andrew Ippoliti
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

Review 3.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 4.  Chlamydospores of Rhizopus microsporus var. rhizopodiformis in tissue of pulmonary mucormycosis.

Authors:  Masatomo Kimura; Kazuko Nishimura; Eisuke Enoki; Takaaki Chikugo; Osamu Maenishi
Journal:  Mycopathologia       Date:  2012-06-26       Impact factor: 2.574

Review 5.  Systemic zygomycosis.

Authors:  E W Benbow; R W Stoddart
Journal:  Postgrad Med J       Date:  1986-11       Impact factor: 2.401

6.  Mucormycosis in the immunocompromised host.

Authors:  S Bhaduri; E Kurrle; E Vanek; R Spanel
Journal:  Infection       Date:  1983 May-Jun       Impact factor: 3.553

7.  Mucormycosis and ameloblastoma of the upper jaw.

Authors:  X Molero; J Canals; A Rilo; A Ortega
Journal:  Infection       Date:  1985 Sep-Oct       Impact factor: 3.553

8.  Apophysomyces elegans: an emerging zygomycete in India.

Authors:  A Chakrabarti; A Ghosh; G S Prasad; J K David; S Gupta; A Das; V Sakhuja; N K Panda; S K Singh; S Das; T Chakrabarti
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

Review 9.  Opportunistic zygomycotic infections. A literature review.

Authors:  A Espinel-Ingroff; L A Oakley; T M Kerkering
Journal:  Mycopathologia       Date:  1987-01       Impact factor: 2.574

10.  Rhizopus arrhizus in Italy as the causative agent of primary cerebral zygomycosis in a drug addict.

Authors:  S Oliveri; E Cammarata; G Augello; P Mancuso; R Tropea; L Ajello; A A Padhye
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.